Not noticing a benefit from sermorelin is a reason to review the plan, not a reason to automatically increase the dose or buy another peptide. The original symptom may have another cause, the expected outcome may not be well supported, or the treatment may simply not be useful for you.

Begin with the goal you and the clinician agreed on. Better sleep, easier daily activity, a laboratory change, and a change on the scale are different outcomes. A useful follow-up examines the one that matters to you alongside side effects, cost, and the limits of the evidence.

The considered take

Reassess the diagnosis, meaningful benefit, and treatment burden. More medicine or more months is not automatically the answer.

Make the original goal measurable

“Feel younger” is difficult to evaluate. A more useful record might describe the everyday activity you hoped would become easier, the sleep problem being assessed, or the symptom that led to the appointment. Write down what was happening before treatment and what has actually changed.

Avoid reconstructing a baseline from memory after several months. If you did not keep notes, say so. A brief, honest account is more helpful than turning ordinary day-to-day variation into a success or failure story. Our results-timeline guide explains why a promotional calendar cannot guarantee a personal response.

Sources: FDA: Managing the benefits and risks of medicines · Endotext: Growth Hormone and Aging

A laboratory response is not every kind of benefit

IGF-1 can provide information about a growth hormone-related response, but a change in the number does not automatically establish improved strength, memory, sleep, or quality of life. Those outcomes need their own assessment.

Do not ask for an ever-higher target simply because you feel the same. Ask the clinician how the result fits the diagnosis, reference range, symptoms, and safety considerations. The clinical-studies guide shows how a hormone change and an everyday benefit can lead to different conclusions.

Sources: Endocrine Society: Adult growth hormone deficiency · Endotext: Growth Hormone and Aging

Review the practical details without blaming yourself

Bring the prescription, current vial label, and a description of how the medicine has been stored and used. Mention missed doses, unclear instructions, a concentration change at refill, or a shipment that arrived outside expected conditions. These details help the pharmacist assess whether the dispensed product and instructions match.

Do not compensate for uncertainty by doubling an amount, changing the mixing liquid, or adding a second product. The dosage guide explains why a syringe marking cannot be carried across different concentrations. If the instructions have been hard to follow, ask for a demonstration that uses your actual supplies.

Sources: Mayo Clinic: Sermorelin injection information · FDA: Compounding questions and answers

Consider other explanations and a stopping decision

Persistent fatigue, weight change, or sleep problems deserve appropriate evaluation. Thyroid disease, sleep disorders, medicines, and other factors may be relevant depending on your history. Read thyroid conditions if that is part of your medical background, rather than assuming every symptom comes from growth hormone.

Ask the clinician what would support continuing, changing course, or stopping. Then check the refill date so a billing cycle does not make the medical decision for you. The long-term use and stopping article and subscription guide cover those separate conversations.

Sources: MedlinePlus: Fatigue · NIDDK: Hypothyroidism · FDA: Managing the benefits and risks of medicines

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
  2. Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.
  3. Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
  4. Mayo Clinic: Sermorelin injection informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
  5. FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
  6. MedlinePlus: FatigueUS National Library of Medicine · Fatigue has many causes that may need evaluation.
  7. NIDDK: HypothyroidismNIH patient education · Symptoms, diagnosis and established thyroid treatment; not a sermorelin trial.